| Filed On | Filing |
|---|---|
| 12 Nov 2026 | 8-K: Results of Operations and Financial Condition |
| 13 Aug 2026 |
8-K: Completion of Acquisition or Disposition of Assets
– Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) – |
| 05 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
Assembly Biosciences, Inc., a Delaware corporation (the “Company”) adopted the Assembly Biosciences, Inc, Second Amended and Restated 2018 Employee Stock Purchase Plan on May 29, 2024 (the “ESPP”). |
| 26 May 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
Introductory. Assembly Biosciences, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 3,358,602 shares of its common stock, p... |
| 22 May 2026 |
8-K: Regulation FD Disclosure; Other Events
– Phase 2 study in cholestatic liver diseases, focused on PBC and PSC, anticipated to initiate in Q1 2027 – |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
– Completed Phase 1b studies for ABI-5366 and ABI-1179, helicase-primase inhibitors for recurrent genital herpes – |
| 30 Mar 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
The 2026 Corporate Bonus Plan (the “Plan”) of Assembly Biosciences, Inc. (the “Company”) is, upon approval by the Compensation Committee (the “Committee”) of the Board of Directors of the Company (the “Board”), effective as of January 1,... |
| 19 Mar 2026 |
8-K: Results of Operations and Financial Condition
– Successfully licensed helicase-primase inhibitor program for recurrent genital herpes to Gilead, including candidates ABI-5366 and ABI-1179, following positive Phase 1b interim data; development plan anticipated by mid-2026 – |
| 08 Dec 2025 |
8-K: Regulation FD Disclosure; Other Events
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital... |
| 10 Nov 2025 |
8-K: Results of Operations and Financial Condition
– Released positive Phase 1b interim results for long-acting helicase-primase inhibitor candidate ABI-5366 showing significant reductions in viral shedding rate and genital lesion rate in recurrent genital herpes – |
| 11 Aug 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
Introductory. Assembly Biosciences, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 5,591,840 shares of its common stock, p... |
| 08 Aug 2025 |
8-K: Regulation FD Disclosure; Other Events
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes |
| 06 Aug 2025 |
8-K: Results of Operations and Financial Condition; Other Events
– On track for proof-of-concept Phase 1b data this no later than this fall in participants with recurrent genital herpes for long-acting herpes simplex virus (HSV) helicase-primase inhibitor candidates, ABI-5366 and ABI-1179 – |
| 25 Jun 2025 |
8-K: Other Events
Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B |
| 09 Jun 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
Assembly Biosciences, Inc., a Delaware corporation (the “Company”) adopted the Assembly Biosciences, Inc, Second Amended and Restated 2018 Employee Stock Purchase Plan on May 29, 2024 (the “ESPP”). |
| 08 May 2025 |
8-K: Results of Operations and Financial Condition
– Ongoing clinical studies for four candidates on track with data expected in 2025, including interim Phase 1b data for long-acting helicase-primase inhibitors ABI-5366 and ABI-1179 anticipated in fall 2025 – |
| 20 Mar 2025 |
8-K: Results of Operations and Financial Condition
– Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline – |
| 20 Feb 2025 |
8-K: Other Events
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes |
| 03 Jan 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
THIS FIRST AMENDMENT TO SUBLEASE (this “Amendment”) is made as of December 30, 2024 by and between ARSENAL BIOSCIENCES, INC., a Delaware corporation (“Sublessor”) and ASSEMBLY BIOSCIENCES, INC., a Delaware corporation (“Sublessee”), with... |
| 26 Dec 2024 |
8-K: Other Events
Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B |
Loading...